Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 2/20 | 0.32 |
| ▸ | ADH1C | P00326 | 1/20 | 0.32 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20087337 | 0.85 | ADH1A (0.40) | ADH1AADH1CSLC18A3 | |
| SCHEMBL27010680 | 0.84 | — | — | |
| SCHEMBL24085914 | 0.81 | ADH1A (0.40) | ADH1AADH1CSLC18A3 | |
| SCHEMBL27010679 | 0.81 | ADH1B (0.34) | ADH1AADH1C | |
| SCHEMBL2807164 | 0.81 | ADH1B (0.34) | ADH1AADH1C | |
| SCHEMBL2806887 | 0.81 | ADH1B (0.34) | ADH1AADH1C | |
| SCHEMBL26620832 | 0.79 | ADH1A (0.36) | ADH1AADH1CSLC18A3 | |
| SCHEMBL12430313 | 0.78 | SLC18A3 (0.40) | ADH1AADH1CSLC18A3 | |
| SCHEMBL12430499 | 0.78 | SLC18A3 (0.40) | ADH1AADH1CSLC18A3 | |
| SCHEMBL26620836 | 0.74 | ADH1B (0.31) | ADH1AADH1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | ADH1A 3222/4885ADH1C 2690/4885SLC18A3 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.